Marion Dorsch is the founder of Atavistik Bio. Atavistik Bio has raised $180M in total funding. Latest round: Series A. Based in Cambridge, USA.
Marion Dorsch is the Co-founder and CEO of Atavistik Bio, a pre-clinical biotechnology company based in Cambridge, Massachusetts. She leads the company's efforts to develop first-in-class drug candidates powered by distinct allosteric control mechanisms. Dorsch founded Atavistik Bio in 2021 to advance genetically-validated targets in metabolic diseases and cancer.
Full founder directory · Investor directory · Company funding database · Fundraising library